Docosanol 10% — Competitive Intelligence Brief

Docosanol 10% (Docosanol 10%) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral agent. Area: Virology/Infectious Disease.

marketed Antiviral agent Viral membrane fusion machinery Virology/Infectious Disease Small molecule

Target snapshot

Docosanol 10% (Docosanol 10%) — Hadassah Medical Organization. Docosanol is a long-chain saturated alcohol that inhibits viral entry and replication by interfering with the fusion of viral and cellular membranes.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docosanol 10% TARGET	Docosanol 10%	Hadassah Medical Organization	marketed	Antiviral agent	Viral membrane fusion machinery
ACYC vehicle	ACYC vehicle	Bausch Health Americas, Inc.	phase 3	Antiviral agent (topical formulation)	Viral DNA polymerase (via acyclovir active ingredient)
Anti-HBV antiviral prophylaxis	Anti-HBV antiviral prophylaxis	Institut de Recherche pour le Developpement	phase 3	Antiviral agent
Antiviral Agents	Antiviral Agents	Pregistry	phase 3	Antiviral agent
Standard of Care Antiviral medications	Standard of Care Antiviral medications	New York Medical College	phase 3	Antiviral agent (class varies by specific drug)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral agent class)

1. Hadassah Medical Organization · 1 drug in this class
2. Institut de Recherche pour le Developpement · 1 drug in this class
3. Pregistry · 1 drug in this class